Clinical Trial Update: Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial update reporting safety and preliminary efficacy data for ATG-017 as monotherapy or in combination with nivolumab in patients with advanced solid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematological Malignancy
• Solid Tumor

Drugs mentioned

• ATG-017 (ATG-017)
• nivolumab (nivolumab)

Snippet

Sponsor: Antengene Therapeutics Limited | Conditions: Solid Tumor, Hematological Malignancy | Phase 1 | Status: TERMINATED